MET and lung adenocarcinoma: In addition, a patient with lung adenocarcinoma and meningeal dissemination of the MET exon 14 skipping mutation was treated with tepotinib as a second-line therapy, which showed a reduction in meningeal dissemination and an improvement in PS.